Insight

Jun 13, 2024, 15:25

A recent study using the SEER-Medicare database by James B. Yu et al.

Aren Karapetyan, Resident at Yerevan State Medical University named after Mkhitar Heratsi, shared on LinkedIn:

“A recent study using the SEER-Medicare database compared gastrointestinal (GI) and genitourinary (GU) toxicity in prostate cancer patients treated with proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT).

The study included patients diagnosed between 2010 and 2017 and matched them based on clinical and sociodemographic factors.

Key Findings:

No significant differences in GI or GU toxicity were observed between PBT and IMRT at 6, 12, and 24 months post-treatment.
GI toxicity rates at 24 months were 20.5% for IMRT and 23.4% for PBT.
GU toxicity rates at 24 months were 28.2% for IMRT and 25.8% for PBT.

This comprehensive analysis suggests that both PBT and IMRT have similar safety profiles regarding GI and GU side effects.

These findings are crucial for informing treatment decisions for localized prostate cancer.”

Source: Aren Karapetyan/LinkedIn

Aren Karapetyan cancer IMRT OncoDaily Oncology PBT prostate cancer SEER-Medicare database Yerevan State Medical University named after Mkhitar Heratsi

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Special Coverage